INTRODUCTION
============

Cervicogenic dizziness is a common condition that results in physical problems such as instability and imbalance; it also produces psychological disorders and disability ([@b22-jer-12-3-216]; [@b27-jer-12-3-216]; [@b31-jer-12-3-216]). [@b40-jer-12-3-216], defined cervicogenic dizziness as "a nonspecific sensation of altered orientation in space and disequilibrium originating from abnormal afferent activity from the neck" which is thought to be caused by disorders in the upper cervical spine and commonly it is associated with cervical stiffness neck pain or headache. Some studies suggest that cervicogenic dizziness is a common symptom present in degenerative changes of the cervical spine, whiplash ([@b19-jer-12-3-216]; [@b37-jer-12-3-216]; [@b40-jer-12-3-216]) or idiopathic neck pain ([@b23-jer-12-3-216]).

Many previous researchers have considered that a disturbance in sensory information from the upper cervical spine may be the cause of this pathology. In addition, cervicogenic dizziness can secondarily alter the inputs integration that is generated by the vestibular (VEST) and visual (VIS) systems. The somatosensory (SOM), VEST and VIS systems are responsible for maintaining balance, but these systems can be occasionally altered and result in neck pain, stiffness and headache ([@b28-jer-12-3-216]). As a result, some research has suggested that a disorder in afferent inputs from any of these systems can produce dizziness and instability ([@b4-jer-12-3-216]; [@b35-jer-12-3-216]). Symptoms that can be recurrent or progressive in patients with chronic neck pain ([@b14-jer-12-3-216]; [@b41-jer-12-3-216]).

It is important to note that patients with chronic, nonspecific neck pain associated with cervicogenic dizziness hold maladaptive beliefs such as a fear of certain movements or pain catastrophizing. Moreover, both dizziness and pain produce a pronounced inability in these kinds of patients ([@b13-jer-12-3-216]; [@b21-jer-12-3-216]). At the same time, cervicogenic dizziness leads to a decrease in neck range of motion (ROM) and a disorder in postural motor control ([@b3-jer-12-3-216]; [@b5-jer-12-3-216]).

Prior scientific evidence has demonstrated the effectiveness of manual therapy in combination with exercises to improve ROM for patients with cervicogenic dizziness ([@b30-jer-12-3-216]; [@b32-jer-12-3-216]; [@b31-jer-12-3-216]). However, these treatments have not proven effective in improving balance and head repositioning accuracy ([@b30-jer-12-3-216]). For this reason we consider it necessary to propose new treatment alternatives for treating patients with cervicogenic dizziness, other models therapeutic exercise could be applied to improve balance and motor control craniocervical of these patients. It is scientifically proven that VEST exercises with a neurophysiological background based in motor learning require a good gaze stability and interactions between the balance system and eye-head coordination ([@b15-jer-12-3-216]; [@b36-jer-12-3-216]).

Our hypothesis is that the combination of therapeutic exercise and education can be a good approach to treat disability, pain, balance and psychological factors involved in the cervicogenic dizziness. There is scientific evidence that the combination of both treatments are effective in the management of various chronic musculoskeletal disorders ([@b1-jer-12-3-216]; [@b7-jer-12-3-216]; [@b9-jer-12-3-216]; [@b8-jer-12-3-216]; [@b29-jer-12-3-216]). However, there has been no research to date about the effectiveness the combination of therapeutic patient education and therapeutic exercise in patients with cervicogenic dizziness.

The primary goal of our investigation is to evaluate the effectiveness of a treatment consisting of therapeutic patient education and exercises for patients with cervicogenic dizziness; we employ the Dizziness Handicap Inventory (DHI) and the Neck Disability Index (NDI).

Our secondary objectives are to evaluate if any changes are produced in ROM, postural control and psychological variables after therapeutic patient education and therapeutic exercise treatment.

MATERIALS AND METHODS
=====================

Participants
------------

The study protocol was approved by the ethics committee of the Centre of University Studies La Salle, Aravaca (CSEULS-PI-052). A consecutive convenience sample of seven patients with cervicogenic dizziness was recruited from the Functional Rehabilitation Institute of The Center for Advanced Studies University La Salle (Aravaca, Madrid, Spain). Prior to enrollment, all patients received explanations regarding the objectives, implications and possible complications of the study; the patients agreed to participate by signing an informed consent form. We reviewed case records dated between October 2014 and June 2015.

Evaluation criteria suggested by [@b40-jer-12-3-216], were established he to exclude patients with other causes of dizziness. These are based on history, physical examination, and vestibular function tests. As used vestibular tests of head impulse test with video-oculography, it is a tool valid and reliability used to measure and quantify semicircular canal function ([@b2-jer-12-3-216]; [@b6-jer-12-3-216]), in addition an assessment of postural control and balance was performed using computerized dynamic posturography. The assessments were made by trained physiotherapists in evaluation and diagnosis of patients with vestibular disorders, according to the inclusion criteria. The inclusion criteria of this prospective case series study included the following: (a) pain and dizziness lasting for at least 3 months; (b) a pain intensity corresponding to at least 3 points on a 10-point numeric pain rating scale; (c) restricted cervical range of movement (flexion, extension, rotation and side-bending); (d) presence of neck pain associated with disability according to the NDI greater than or equal to 5 points; (e) presence of subjective dizziness associated with pain, movement, stiffness or specific postures of the cervical region; and (f) men and women between 18 and 65 yr old. The exclusion criteria consisted of the following: (a) presence of trauma or recent surgery to the head, face, neck or chest; (b) specific diagnosis of central or peripheral dizziness; (c) history of previous physical-therapy intervention for the cervical region; (d) any cognitive impairment that hindered viewing of audiovisual material; (e) difficulty understanding or communicating; or (f) inadequate understanding of the Spanish language to follow instructions for measuring and treatment.

Procedures
----------

Each of the eligible patients was asked to complete a basic questionnaire to determine if he she met the criteria for inclusion or exclusion. This questionnaire included demographic data (gender, age, height, and weight), a body chart in which patients had to mark the location of their pain, and several questions about the characteristics of their pain. In addition, the patients completed several self-report measures related with disability, pain and psychological variables. All the patients received a manual physical examination including an assessment of the cervical and thoracic region, an evaluation of their cervical ROM and a full assessment of their postural control performed using computerized dynamic posturography. These self-reports and physical tests were conducted on the day of the first measurement (baseline) and again after the follow-up period.

Primary outcome measures
------------------------

The primary outcome measures used in this prospective case series were the DHI and NDI. The DHI is a specific self-perceived questionnaire that assesses the patient's condition and the effect of dizziness on the patient's quality of life. The DHI consists of 25 questions that classify the effects of dizziness in three categories: Physical, functional and emotional. The Spanish version of the DHI is a valid and reliable questionnaire that has high internal consistency. It has been suggested that a change in score of 10% or more is clinically relevant ([@b35-jer-12-3-216]).

The Spanish version of the NDI measures perceived neck disability. This questionnaire consists of 10 items (seven questions related to daily living activities, two questions related to pain and one question related to concentration); each item is scored from 0 (no disability) to 5 (complete disability) points. The NDI has demonstrated acceptable psychometric properties. It has been suggested that a change in score of 10% or more is clinically relevant, and 5 points indicates the minimal detectable change ([@b24-jer-12-3-216]).

Secondary outcome measures
--------------------------

We assessed postural control via a sensory organization test (SOT) on a SMART EquiTest system (Neurocom International Inc., Clackamas, OR, USA). The SOT is a component of computerized dynamic posturography that assesses the relative contributions of VIS, VEST, and SOM systems during standing by disturbing the information delivered to the patient's eyes, feet and joints ([@b41-jer-12-3-216]).

For the SOT, the subjects performed three 20-sec trials, each under six different sensory conditions of increasing difficulty (18 measurements total): (a) eyes open; (b) eyes closed; (c) eyes open with surround sway; (d) eyes open with support surface sway; (e) eyes closed with support surface sway; (f) eyes open with surround and support surface sway. A percentage score is calculated for each trial, including four ratios based on the ability to use VIS, VEST, and SOM pathways and a composite score to determine overall postural stability. The four ratios of sensory analysis are SOM, VIS, VEST, and visual preference (PREF). We found that the SOT had adequate validity and reliability when measuring different pathological conditions in both symptomatic and asymptomatic subjects ([@b13-jer-12-3-216]; [@b14-jer-12-3-216]; [@b21-jer-12-3-216]). In addition, the minimum detectable change (MDC) data are presented for somatosensorial, VEST, and VIS ratios in [Table 1](#t1-jer-12-3-216){ref-type="table"} ([@b10-jer-12-3-216]).

We measured cervical ROM using a cervical goniometer called a CROM. This device has three inclinometers, one at each plane of movement. A plastic glasses-like support houses two of the inclinometers that enables measurements of flexion, extension and side-bending of the neck. Adding another part of the device with the third inclinometer and magnets around the neck allows rotations to be measured. All movements had to be done without pain. In some of the subjects the movement had to be hand-guided to achieve a proper movement. This procedure has demonstrated its reliability in patients with neck pain ([@b5-jer-12-3-216]). The MDC of cervical ROM is described in [Table 2](#t2-jer-12-3-216){ref-type="table"} for all movements ([@b16-jer-12-3-216]).

The Spanish version of the Pain Catastrophizing Scale (PCS) assesses the degree of pain catastrophizing. The PCS includes 13 items and a three-factor structure: rumination, magnification and helplessness ([@b17-jer-12-3-216]). The theoretical point range is between 0 and 52; lower scores correspond to less catastrophizing. The MDC of PCS is 9.1 points ([@b18-jer-12-3-216]).

We used the Spanish version of the TSK-11 to assess pain-related fear of movement. The TSK-11 is a modified version with 11 items of greater importance and greater validity and reliability. The MDC of the TSK-11 is 4.8 points ([@b18-jer-12-3-216]; [@b39-jer-12-3-216]).

We assessed self-efficacy using the Spanish version of the CPSS. The scale was developed to measure the perceived self-efficacy and ability to cope with the consequences of pain in chronic pain patients. This scale consists of 19 items and three domains that assess self-efficacy for pain management, physical functioning and coping with symptoms. The Spanish version of the CPSS has been demonstrated to have acceptable psychometric properties (internal consistency, α=0.91) ([@b26-jer-12-3-216]).

Interventions
-------------

The patients underwent eight treatment sessions, two sessions per week for four weeks with a follow-up of 10 and 15 days after the last session. The treatment was based on a combination of therapeutic exercises and therapeutic patient education. In the first four sessions, the patients were educated about chronic neck pain neurophysiology, chronic neck pain related to dizziness physiopathology, the benefits of therapeutic exercise, and active coping strategies for pain ([Table 3](#t3-jer-12-3-216){ref-type="table"}).

During the first four sessions, motor control and ROM exercises were prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM in flexion, rotation and inclination. These exercises were performed at a rate of 3--4 sets and an intensity of 12--15 repetitions per day (Supplementary material).

During the last four sessions, maximum strength exercises were prescribed in order to improve the strength of flexors, rotators and inclinators muscles with an intensity of 2--3 sets of 5--7 repetitions per day (isometric contraction), in addition to oculomotor exercises in order to decrease dizziness (Supplementary material 1). These exercises have been described in previous studies ([@b25-jer-12-3-216]; [@b33-jer-12-3-216]; [@b40-jer-12-3-216]).

The patients were instructed to stretch the major muscles of their cervical spine after all exercise sessions. In addition, the patients were encouraged to remember their lessons that they had learned in the first two weeks of instruction.

The exercises were guided by a trained physiotherapist who first explained the exercises and then demonstrated the exercises herself. Next, the patients repeated the exercises under supervision to ensure that their form was correct.

All of the patients were given a copy of the exercise instructions on paper. Patients were instructed to complete these exercises 4 times per week.

Statistical analysis
--------------------

We analyzed data from seven patients using IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). The normal distribution of the majority of variables was confirmed using the Shapiro--Wilk test (*P*\>0.05). We used descriptive statistics to summarize the data of continuous variables; these variables are presented as mean±standard deviation and a 95% confidence interval. We used the Student *t*-test to compare the outcomes of continuous variables. We also calculated the percentage of change for each variable. The effect sizes (Cohen *d*) were calculated for the outcome variables. According to Cohen method, the magnitude of the effect was classified as small (0.20--0.49), medium (0.50--0.79), or large (≥0.8). A value of *P*\<0.05 was considered to be statistically significant ([@b12-jer-12-3-216]).

RESULTS
=======

We evaluated 10 patients before treatment, but only seven patients (two males, five females) underwent a treatment based on education plus therapeutic exercise. The mean age of our patient cohort was 38.43 yr (range, 24--62 yr). All of the patients complained of cervicogenic dizziness and had had nonspecific chronic neck pain for at least 3 months; the average duration of pain duration prior to the procedure was 28.29 months (range, 6--60 months). None of the patients had a history of trauma ([Table 4](#t4-jer-12-3-216){ref-type="table"}).

In terms of the individual pre-post data, the participants showed an improvement in psychosocial variables ([Table 5](#t5-jer-12-3-216){ref-type="table"}). On the NDI questionnaire, 71.43% of the subjects showed a change over the MDC (5 points). In the catastrophizing variable, 57.14% of the sample improved their score over the MDC by reducing their score by at least 9.1 points. In the fear of movement variable, just two people exhibited a change over the MDC (4.8 points). Nearly one half of our patients (42.86%) exhibited an improvement over the MDC on the DHI.

Moreover, our mean results exhibited significant changes in fear of movement (*P*=0.20) and catastrophism (*t*=3.154, *P*=0.005). Furthermore, the mean results of the PCS questionnaire showed a significant improvement (*t*=4.289, *P*\<0.01). In addition, the mean scores of the functional and physical subscale of disability owing to dizziness showed changes that were statically relevant: *t*=2.976, *P*=0.025 and *t*=3.771, *P*=0.009, respectively. The total score of this test also revealed differences between the first and second measurements: *t*=3.688, *P*=0.010. The NDI suffered a significant decrease (*t*=6.000, *P*=0.001).

We also analyzed physical variables. We observed an improvement in the mean data of rotation comparing the results pre- and posttreatment with a statistical significance of *t*=−3.543, *P*=0.012 in right rotation and *t*=−2.865, *P*=0.029 in left rotation. Cervical rotation improved over the MDC (5.5° right, 5.4° left) in 71.43% of the sample, and left rotation improved over the MDC in 57.14% of the sample. For movements in the sagittal plane, the data exhibited an improvement of 42.86% for cervical flexion and 28.57% for extension. Our data did not reveal any improvement over the MDC in the frontal plane ([Table 2](#t2-jer-12-3-216){ref-type="table"}).

Dynamic posturography that was conducted before and after treatment revealed statistically significant differences in PREF score during the SOT (*t*=−2.515, *P*=0.046) ([Table 1](#t1-jer-12-3-216){ref-type="table"}). Treatment with education and therapeutic exercise yielded changes in the fear of movement, catastrophizing, NDI and disability because of dizziness scores. Moreover, this treatment played a role in reported improvements in physical variables such as neck rotation ROM and PREF during balance tests.

DISCUSSION
==========

The main outcome of this intervention study was focused on the evaluation of the efficacy of therapeutic patient education and therapeutic exercise as interventions for physical and psychological complaints of patients with cervicogenic dizziness. Our results showed that patients with cervicogenic dizziness treated with therapeutic patient education and therapeutic exercise experienced benefits in neck disability, handicap dizziness, catastrophizing, neck pain, and self-efficacy. Fortnight lapse was left between evaluations for comparison as a clinically reasonable period of time for checking the effects of the intervention on dizziness. We measured effect sizes at follow-up at 6 weeks; the reduction was not only statically significant also clinically meaningful for ROM in the transversal plane, catastrophism, and disability associated with dizziness and neck pain.

Our results identified only three patients with a MDC (42.85%). [@b11-jer-12-3-216], demonstrated different results using a mechanical approach in which patients improved in physical and functional DHI. However, the emotional dimension of the test showed no difference. Moreover, these authors suggested including therapeutic patient education as a therapy in order to change the emotional construct of the DHI questionnaire. According to our results, therapeutic patient education may play a role as a treatment for emotional components related to dizziness.

When we used the DHI for severity classification, five participants (71.42%) changed from have a moderate or severe condition to a better classification by the end of the intervention. Three participants (42.85%) initially had a disorder classified as severe. These participants were all older than 43 years. We did not find any statistically significant correlations between severity of dizziness and age, but a larger sample size might be able to identify such a trend. A study conducted by [@b34-jer-12-3-216] described severe impairments related to dizziness in older adults (at least 70 yr old). This cohort received therapeutic exercise and therapeutic patient education and exhibited improvements in DHI total score ([@b34-jer-12-3-216]).

Our results are consistent with those of [@b38-jer-12-3-216]. This study was conducted with patients that had reported VEST chronic dysfunction, dizziness, balance impairment, or other unspecific dizziness sensations for at least three months. It was observed in DHI when performing cervical manual therapy, exercises and balance training ([@b38-jer-12-3-216]). An intervention without education yielded similar effects as our combined approach with an improvement in both variables. Larger studies must be conducted in order to demonstrate the potential therapeutic effect of education in isolation.

In terms of neck disability, 71.42% of our sample attained the MDC after an intervention based on therapeutic patient education and therapeutic exercise. In addition, we found changes in ROM. Four patients attained the MDC on the transversal plane ROM to the right (left). In terms of at cervical ROM in the sagittal plane, we observed that 42.85% showed clinically relevant difference for the flexion and 28.5% for the extension. Previous research by [@b30-jer-12-3-216], proposed clinically relevant changes could be observed only when performing manual therapy and therapeutic exercise.

Our results related to postural control and balance showed that there were no statistical differences at a 6-week follow-up with the intervention we proposed. Similar results (eyes-closed test performed during SOT at the baseline) were consistent with the results reported by [@b30-jer-12-3-216], but no changes were reported for SOT when performing manual therapy and therapeutic exercise for the treatment of patients with cervicogenic dizziness.

Our data related to disability and some psychosocial factors as kinesiophobia and catastrophism showed a clinically relevant improvement for kinesiophobia in two participants and same results for catastrophizing in four participants. Our findings are consistent with the findings of [@b34-jer-12-3-216], who used a therapeutic intervention of therapeutic patient education and exercise. [@b20-jer-12-3-216] also reported similar results for VEST rehabilitation and education.

According to the literature, there are no clear guidelines for evidence-based treatment planning. Manual therapy and VEST rehabilitation are the state of the art, but additional research is necessary for supporting these therapies as effective treatments.

To the best of our knowledge, this study is the first to provide preliminary evidence that therapeutic exercise associated with therapeutic patient education may play a beneficial role when the outcomes of the treatment are focused on decreasing dizziness in patients with cervicogenic dizziness.

In summary, the results of our study show that treatment with therapeutic patient education and therapeutic exercise for patients with cervicogenic dizziness seems to be beneficial in decreasing neck disability and dizziness disability. Moreover, this treatment could be useful for managing psychosocial factors in patients with high levels of catastrophizing and fear of movement. Finally, we conclude that it is appropriate to combine this treatment with another therapy when ROM is impaired. However, our study exhibited an improvement in cervical rotation, and this finding could be related to a decrease in the feeling of dizziness as reported in the HDI. We anticipate that our work will motivate long-term follow-up intervention studies with larger sample sizes in order to verify the effectiveness of therapeutic patient education and therapeutic exercise in the clinical management of patients with cervicogenic dizziness.

SUPPLEMENT MATERIAL
===================

EXERCISES
---------

General guidelines for chronic nonspecific neck pain associated to cervicogenic dizziness.

-   Mobilization exercises

    1.  \- It is the first phase of exercises. The patients are trained by a physiotherapist to do a correct performance of the exercises.

    2.  \- The main goal of this phase is to increase the range of motion in a no pain condition.

-   Control motor exercise

    1.  \- It is an exercise included in the second phase in which patients learned by a physiotherapist to perform the exercises in a correct way.

    2.  \- The patients are informed about the importance of having a good cervical motor control.

    3.  \- The main goal of this exercise is to increase the motor control of deep neck flexors to improve the stability of cervical spine.

-   Oculomotor exercises

    1.  \- It is the third phase of exercises. Patients are taught by the physiotherapist to perform the exercises in a correct way.

    2.  \- The main goal is to reduce the dizziness symptom, the gaze control and postural control.

-   Strength exercises

    1.  \- This is then fourth phase. Patients are taught to perform the exercise in a correct way.

    2.  \- The main goal of this phase is to improve the strength of cervical muscles and also their strength-endurance.

MOBILIZATION EXERCISES
----------------------

![1) Flexion: Try to touch your chest with your chin. This exercise should be done for 4 days/week and the frequency is 10 times ×3 sets.](jer-12-3-216f1){#f1-jer-12-3-216}

![2) Rotation: Turn your head to the right and left making a stop in the middle of the range. This exercise should be done for 4 days/week and the frequency is 3 sets ×10 times.](jer-12-3-216f2){#f2-jer-12-3-216}

![3) Lateral flexion: Tilt your head to the right and to the left making a stop in the middle of the range keeping your shoulders down. This exercise should be done for 4 days/week and the frequency is 3 sets ×10 times.](jer-12-3-216f3){#f3-jer-12-3-216}

MOTOR CONTROL EXERCISE
----------------------

![1) Crane-cervical flexion: Put an elastic band on the occipital bone and hold it with your hands maintaining your arms in a 90˚ angle.\
2) Bring your chin forward. Then bring it back against the band.](jer-12-3-216f4){#f4-jer-12-3-216}

OCULOMOTOR TRAINING
-------------------

![1) Set a fixed point in front of your eyes. Turn your head to both sides keeping your eyes on your thumb.](jer-12-3-216f5){#f5-jer-12-3-216}

![2) Set a fixed point in front of your eyes. Close your eyes. Turn your head with eyes closed and try to put your head in the initial position. Open your eyes and check it.](jer-12-3-216f6){#f6-jer-12-3-216}

![3) Extend your arm to the right side and try to turn your head to the front keeping your gaze looking at your thumb. Then repeat the exercise to the other side using your left arm.](jer-12-3-216f7){#f7-jer-12-3-216}

![4) Extend your arms in front you with your thumbs in front of your eyes. Your thumbs should be separated by 7--10 cm. Then try to look at both thumbs at the same time making your eyes move side to side.](jer-12-3-216f8){#f8-jer-12-3-216}

STRENGTH EXERCISES
------------------

Contract for 5 sec. The frequency of exercise is 3 sets × 10 times.

![1) Flexion: Put one hand in the front of your head and perform the same force against your hand.](jer-12-3-216f9){#f9-jer-12-3-216}

![2) Extension: Place your hands behind your head and perform opposing forces.](jer-12-3-216f10){#f10-jer-12-3-216}

![3) Rotation: Put one of your hands in the side of your forehead and make the force in the direction that will make turn to the left or right your head.](jer-12-3-216f11){#f11-jer-12-3-216}

![4) Lateral Flexion: Place your hand on your temporalis muscle and make lateral flexion in an isometric exercise making opposing forces.](jer-12-3-216f12){#f12-jer-12-3-216}

STRETCHING
----------

![Trapezium 1: Put your hand on your head as shown in the photograph. Keep your shoulders down. Then bring your head down to stretch trapezium muscle. Then repeat it to the other side.](jer-12-3-216f13){#f13-jer-12-3-216}

![Trapezium 2: Put your hand on your temporal muscle as shown in the photograph. And bring your head down stretching the muscle.](jer-12-3-216f14){#f14-jer-12-3-216}

![Sternocleidomastoid: Put your hand on temporal bone, extend your head tilt your head and turn it to the opposite side. Then let your head fall in that position.](jer-12-3-216f15){#f15-jer-12-3-216}

![Rhomboid: Cross your arms and put both hands separated over the scapulae. You should make opposing forces with both hands keeping your shoulders down.](jer-12-3-216f16){#f16-jer-12-3-216}

![Pectoralis major: Put your hand on a wall or a door frame, then turn your body guiding your chest to the opposite side.](jer-12-3-216f17){#f17-jer-12-3-216}
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###### 

Dynamic posturography sensory organization test

  Measure                      Somatosensory ratio          Visual ratio                Vestibular ratio             Visual preference
  ---------------------------- ---------------------------- --------------------------- ---------------------------- ---------------------------------------------------------------------------
  Subject 1                                                                                                          
   Baseline                    1.01                         0.97                        0.79                         0.68
   Follow-up                   0.99                         0.95                        0.81                         1.00
                                                                                                                     
  Subject 2                                                                                                          
   Baseline                    0.92                         0.85                        0.90                         1.00
   Follow-up                   0.99                         0.99                        0.78                         1.92
                                                                                                                     
  Subject 3                                                                                                          
   Baseline                    0.97                         0.98                        0.73                         0.91
   Follow-up                   0.95                         0.97                        0.80                         1.01
                                                                                                                     
  Subject 4                                                                                                          
   Baseline                    0.99                         0.97                        0.66                         1.06
   Follow-up                   0.98                         0.94                        0.74                         0.99
                                                                                                                     
  Subject 5                                                                                                          
   Baseline                    0.93                         0.90                        0.84                         0.73
   Follow-up                   1.00                         1.00                        0.78                         0.98
                                                                                                                     
  Subject 6                                                                                                          
   Baseline                    0.94                         0.83                        0.73                         0.84
   Follow-up                   1.00                         0.97                        0.78                         1.01
                                                                                                                     
  Subject 7                                                                                                          
   Baseline                    0.97                         0.97                        0.56                         0.60
   Follow-up                   0.90                         0.43                        0.45                         1.02
                                                                                                                     
  Mean±SD                                                                                                            
   Baseline                    0.96±0.034                   0.92±0.06                   0.74±0.11                    0.83±0.16
   Follow-up                   0.97±0.036                   0.89±0.20                   0.73±0.12                    1.13±0.34
                                                                                                                     
  Mean diference±SD (95% CI)   −0.11±0.56 (−0.06 to 0.04)   0.03±0.23 (−0.18 to 0.25)   0.009±0.08 (−0.06 to 0.08)   −0.29±0.31 (−0.59 to −0.008)[\*](#tfn2-jer-12-3-216){ref-type="table-fn"}
                                                                                                                     
  Effect size Cohen *d*        −0.28                        0.20                        0.087                        −1.13
                                                                                                                     
  %\>MDC                       95% CI, 10.08                95% CI, 11.93               95% CI, 25.69                \-

SD, standard deviation; CI, confidence interval; MDC, minimum detectable change.

*P*\<0.05, statistically significance.

###### 

Range of motion

  Measure                      Flexion                                             Extension                                           Right rotation                                                              Left rotation                                                               Right lateral flexion      Left lateral flexion
  ---------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------- ---------------------------------------------------
  Subject 1                                                                                                                                                                                                                                                                                                               
   Baseline                    64.60                                               79.00                                               81.00                                                                       80.60                                                                       54.00                      50.00
   Follow-up                   50.00                                               94.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}   86.60[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           76.60                                                                       50.00                      52.60
                                                                                                                                                                                                                                                                                                                          
  Subject 2                                                                                                                                                                                                                                                                                                               
   Baseline                    57.00                                               70.00                                               64.00                                                                       65.00                                                                       41.30                      53.30
   Follow-up                   60.00                                               80.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}   67.30                                                                       69.00                                                                       44.60                      50.00
                                                                                                                                                                                                                                                                                                                          
  Subject 3                                                                                                                                                                                                                                                                                                               
   Baseline                    35.00                                               60.00                                               61.0                                                                        62.00                                                                       43.00                      46.00
   Follow-up                   55.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}   61.30                                               70.60[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           72.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           38.66                      40.66
                                                                                                                                                                                                                                                                                                                          
  Subject 4                                                                                                                                                                                                                                                                                                               
   Baseline                    45.00                                               59.30                                               54.60                                                                       46.60                                                                       49.30                      32.00
   Follow-up                   61.30[†](#tfn5-jer-12-3-216){ref-type="table-fn"}   50.00                                               67.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           64.60[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           28.60                      30.60
                                                                                                                                                                                                                                                                                                                          
  Subject 5                                                                                                                                                                                                                                                                                                               
   Baseline                    53.33                                               89.00                                               72.00                                                                       74.00                                                                       48.66                      54.00
   Follow-up                   70.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}   72.66                                               75.30                                                                       80.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           42.66                      54.66
                                                                                                                                                                                                                                                                                                                          
  Subject 6                                                                                                                                                                                                                                                                                                               
   Baseline                    49.30                                               41.33                                               50.60                                                                       58.60                                                                       31.00                      36.00
   Follow-up                   43.30                                               50.00                                               61.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           69.00[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           32.60                      42.60[†](#tfn5-jer-12-3-216){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                          
  Subject 7                                                                                                                                                                                                                                                                                                               
   Baseline                    58.00                                               58.00                                               68.66                                                                       68.66                                                                       37.33                      42.00
   Follow-up                   58.00                                               60.00                                               68.00                                                                       75.30[†](#tfn5-jer-12-3-216){ref-type="table-fn"}                           42.00                      43.33
                                                                                                                                                                                                                                                                                                                          
  Mean±SD                                                                                                                                                                                                                                                                                                                 
   Baseline                    51.7±9.7                                            65.2±15.6                                           65.0±72.3                                                                   64.5±10.4                                                                   44.7±8.5                   43.4±7.8
   Follow-up                   56.8±8.5                                            66.8±16.2                                           72.3±5.2                                                                    70.8±8.17                                                                   44.9±8.27                  39.8±7.2
                                                                                                                                                                                                                                                                                                                          
  Mean diference±SD (95% CI)   −5.05±13.05 (−17.12 to 7.02)                        −1.61±11.11 (−11.89 to 8.65)                        −6.27±4.68 (−10.61 to −1.94)[\*](#tfn4-jer-12-3-216){ref-type="table-fn"}   −7.29±6.73 (−13.51 to −1.06)[\*](#tfn4-jer-12-3-216){ref-type="table-fn"}   3.6±8.58 (−4.29 to11.57)   −0.16±3.95 (−3.81 to 3.49)
                                                                                                                                                                                                                                                                                                                          
  Effect size Cohen *d*        −0.56                                               −0.1                                                0.01                                                                        −0.45                                                                       −0.02                      0.48
                                                                                                                                                                                                                                                                                                                          
  \% \>MCD                     6.5˚                                                9.3˚                                                5.5˚                                                                        5.4˚                                                                        5.9˚                       5.9˚

SD, standard deviation; CI, confidence interval; MDC, minimum detectable change.

*P*\<0.05, statistically significance.

MDC\.

###### 

Therapeutic patients education

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Education                      1st Session                                                      2nd Session                                                                                            3th Session                                                      4th Session                                       5th--8th Session                                                                                                                                                                                                                                                                                                    
  ------------------------------ ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------
  Pain\                          Education on basic physiology and chronic pain                   Explanation of causes and consequences of pain\                                                        Education on basic physiology in chronic pain                    Explanation of central sensitization processes\   Education on cervical dysfunction                                 Explanation of neck muscle function and the upper cervical joint implications   Education on benefits of exercise                                Explanation of neurophysiological effects of exercise and its effects on psychological factors   Concepts review Implementation of the exercises
   physiology education                                                                           Explanation of characteristics of acute vs chronic pain and the implications of chronic pain in life                                                                    Explanation of psychological factors                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Pain coping skills education   Goal setting\                                                    Mobilization exercises Stretching                                                                      Goal setting\                                                    Mobilization exercises\                           Goal setting\                                                     Mobilization exercises\                                                         Goal setting\                                                    Mobilization exercises\                                                                          
                                 Perform the activities and exercises daily or when prescribed\                                                                                                          Perform the activities and exercises daily or when prescribed\   Motor control exercise stretching                 Perform the activities and exercises daily or when prescribed.\   Motor control exercise\                                                         Perform the activities and exercises daily or when prescribed\   Motor control exercise\                                                                          
                                 Active lifestyle                                                                                                                                                        Active lifestyle                                                                                                   Active lifestyle                                                  Vestibular exercises\                                                           Active lifestyle                                                 Vestibular exercises\                                                                            
                                                                                                                                                                                                                                                                                                                                                                                              And stretching                                                                                                                                   Strength exercises\                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Stretching                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Descriptive variables

  Case      Gender   Age (yr)      Height (cm)   Pain duration (mo)   NPRS
  --------- -------- ------------- ------------- -------------------- -----------
  1         Female   35            170           6                    7
  2         Female   24            163           60                   7
  3         Female   24            162           24                   6
  4         Male     50            178           24                   3
  5         Female   31            160           12                   9
  6         Male     62            172           60                   5
  7         Female   43            155           12                   7
  Mean±SD   \-       38.43±14.10   165.72±7.93   28.29±22.64          6.29±1.89

NPRS, numerical pain rating scale; SD, standard deviation.

###### 

Psychosocial variables

  Measure                       NDI                                                                        DHI                                                                      DHI physical                                                            DHI functional                                                        DHI emotional               PCS                                                                       TSK-11                                                                CPSS
  ----------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------
  Subject 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     6                                                                          6                                                                        6                                                                       0                                                                     0                           4                                                                         13                                                                    56
   Follow-up                    5                                                                          6                                                                        4                                                                       2                                                                     0                           0                                                                         11                                                                    190
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Subject 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     12                                                                         18                                                                       10                                                                      6                                                                     2                           17                                                                        14                                                                    138
   Follow-up                    6[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                             14                                                                       8                                                                       4                                                                     2                           3[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                            12                                                                    187
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Subject 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     15                                                                         22                                                                       12                                                                      8                                                                     2                           27                                                                        24                                                                    144
   Follow-up                    11                                                                         6[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                           4                                                                       2                                                                     0                           4[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                            17[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                       186
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Subject 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     9                                                                          6                                                                        2                                                                       2                                                                     2                           6                                                                         21                                                                    175
   Follow-up                    4[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                             0                                                                        0                                                                       0                                                                     0                           1                                                                         18                                                                    190
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Subject 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     12                                                                         28                                                                       12                                                                      8                                                                     8                           16                                                                        19                                                                    167
   Follow-up                    4[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                             18                                                                       10                                                                      4                                                                     4                           2[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                            20                                                                    174
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Subject 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     15                                                                         32                                                                       12                                                                      14                                                                    6                           13                                                                        29                                                                    150
   Follow-up                    10[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                            20[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                          4                                                                       10                                                                    6                           8                                                                         26                                                                    147
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Subject 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Baseline                     19                                                                         34                                                                       16                                                                      10                                                                    8                           28                                                                        21                                                                    138
   Follow-up                    12[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                            14[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                          8                                                                       4                                                                     2                           12[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                           16[†](#tfn10-jer-12-3-216){ref-type="table-fn"}                       144
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Mean±SD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Baseline                     12.57±4.27                                                                 20.85±11.53                                                              9.43±4.99                                                               6.86±4.74                                                             4±3.27                      15.86±9.29                                                                20.14±5.55                                                            138.28±38.97
   Follow-up                    7.43±3.45                                                                  11.14±7.28                                                               6±3.65                                                                  3.71±3.15                                                             2±2.3                       4.28±4.27                                                                 17.14±5.04                                                            174.00±20.22
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Mean diference±SD (95% CI)    5.14±2.27.28 (3.04--7.24)[\*\*](#tfn9-jer-12-3-216){ref-type="table-fn"}   9.71±6.96 (3.26--16.15)[\*\*](#tfn9-jer-12-3-216){ref-type="table-fn"}   4.57±3.20 (1.60--7.53)[\*\*](#tfn9-jer-12-3-216){ref-type="table-fn"}   3.14±2,79 (0.55--5.72)[\*](#tfn8-jer-12-3-216){ref-type="table-fn"}   2.00±2.30 (−0.13 to 4.13)   11.57±7.13 (4.96--18.17)[\*\*](#tfn9-jer-12-3-216){ref-type="table-fn"}   3.00±2.51 (0.67--5.32)[\*](#tfn8-jer-12-3-216){ref-type="table-fn"}   −35.71±47.45 (−79.60 to 8.17)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Effect size Cohen *d*         1.32                                                                       1.01                                                                     0.78                                                                    0.78                                                                  0.62                        1.6                                                                       0.56                                                                  −1.15
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \% \>MCD                      5                                                                          11                                                                       \-                                                                      \-                                                                    \-                          9.1                                                                       4.8                                                                   \-

NDI, Neck Disability Index; DHI, Dizziness Handicap Inventory; TSK, Tampa Scale Kinesofobia; PCS, Pain Catastrophism Scale; CPSS, Chronic Pain Self-Efficacy Scale; SD, standard deviation; CI, confidence interval; MDC, minimum detectable change.

*P*\<0.05, statistically significance.

Significance *P*\<0.01.

MDC\.
